Efficacy and Safety of Tofacitinib in Patients With Total and Universal Alopecia: A Retrospective Evaluation of 69 Patients

This retrospective study assessed the efficacy and safety of tofacitinib in 69 patients with alopecia totalis and alopecia universalis over a median of 6 months. It found that 47.8% of patients had a significant reduction in the Severity of Alopecia Tool (SALT) score, and 26.1% experienced complete hair regrowth. Younger age at onset of alopecia areata and shorter treatment duration were linked to poorer outcomes. Adverse effects were mostly mild, such as acneiform rash and folliculitis. The study concluded that tofacitinib is effective for these conditions, with significant improvements noted at 24 and 36 weeks, though the single-center design and small sample size are limitations.